Market Cap 1.34B
Revenue (ttm) 0.00
Net Income (ttm) -105.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,641,200
Avg Vol 1,217,748
Day's Range N/A - N/A
Shares Out 57.91M
Stochastic %K 8%
Beta 0.42
Analysts Strong Sell
Price Target $53.60

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
OliverDog
OliverDog Jul. 4 at 5:03 PM
$CAPR employee incentive stock options As is very common with employee incentive option plans, Capricor's plan requires that employees holding options at the time they leave the company have to exercise any of those options within a month or so of leaving. After that window, the Company cancels the options. That is, they can hold shares bought with the options but not the options themselves. Now, the CFO and chief legal officer have recently sold a large number of shares each, shares they received after exercising options. Why? I don't think it is lack of confidence in the future of the Company. I think it is more likely it is preparation for the day their remaining vested options will be exercised, namely once the Board draws conclusions about who is most responsible for the "mistake" (#$%) in the Company's distribution agreement with NS. My speculation. It is what I would do in their position.
3 · Reply
satrasal
satrasal Jul. 4 at 3:30 PM
$CAPR I haven't read the NS brief. I'm sure it is immaterial. The arbitration carve-out in the Capricor-NS Pharma agreement does not say "except for preliminary injunctions." It exempts claims for "temporary, preliminary, or permanent injunctive relief or any other form of equitable relief." And rescission is an equitable remedy. Since equitable relief is exempt from arbitration, and since Chancery now properly takes the case to evaluate injunction, it retains jurisdiction to handle the entire case, given Judge Neal remanded the entire case and denied NS Pharma’s motion to compel arbitration. Frustration of purpose is central, and NS has plainly admitted contract unworkability. So I think we get both an injunction and rescission from Chancery. Capr moved back up the 30ish before the adcom drop to support at 22ish. The market agrees - since sept expiry premium is .5 to 1 more than Aug aug 21 expiry, despite including the pdufa; any movement is retail gaming, not instit repositioning.
1 · Reply
Dash_Man
Dash_Man Jul. 4 at 2:17 PM
$CAPR Happy 4th everyone. I am hoping Skadden highlight this logical inconsistency in their reply.
1 · Reply
Sherwoodtf
Sherwoodtf Jul. 4 at 10:30 AM
$CAPR https://www.parentprojectmd.org/events/webinar-your-voice-matters-preparing-for-the-fda-advisory-committee-meeting-on-deramiocel/?fbclid=IwZnRzaAS1v95leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeh6_D17nv_78-ec8Os9scEqBYX5lYkJnpfUdXxvdxb_nEZV-F2g5wHk_bLbc_aem_jBlIcg8d2aacU4DUAaMx7A
2 · Reply
Svenson1984
Svenson1984 Jul. 4 at 10:04 AM
$CAPR I love Capr but I am also not married to the stock. Sold shares some when Abvx dipped to the 80s as I know this was an easy short term gain. Made all the losses back from the $35 fade. Might trim my Abvx position next to by more here or SLS
0 · Reply
HamBoneXoXo
HamBoneXoXo Jul. 4 at 1:53 AM
$CAPR I would not be holding long shares in advance of adcom briefing papers because in this case, the briefing won’t be positive considering that this adcom actually coming post crl where fda rejected the drug. The briefing will be mixed to negative suggesting fda remains open to discussion but questions the validity of the efficacy analysis.
3 · Reply
nickiead
nickiead Jul. 3 at 11:51 PM
$CAPR If the court grants Capricor a preliminary injunction then it stops NS Nippon from distributing drug. The court case would continue and Capricor would distribute Deramiocel and establish a distribution network. A case like this could last for many months and possibly over a year. And although arbitration would ultimately be part of final resolution it would come at end of case not during. Capricor would then just be arbitrating a cash settlement. Bottomline if Capricor gets a temporary injunction it will basically end NS Pharma as a distributor now and in future. Nippon is desperately fighting the "irreparable harm" claim which is their only hope to stop injunction. Skadden has outlined such a strong case of proving "irreparable harm" that odds are very likely we see an expedited hearing with oral arguments in a few weeks and a preliminary injunction soon after.
1 · Reply
Jusbabysteppin
Jusbabysteppin Jul. 3 at 10:52 PM
$CAPR My bottom line is this, NS is coming after us because they want what we have. Tough shit for them , I think it’s a great sign of progress. They are first to come after capr, but more will come . After all, it’s like Willy Wonkas golden ticket! Everyone wants it!
2 · Reply
ReggieTrades
ReggieTrades Jul. 3 at 10:46 PM
1 · Reply
sueandray
sueandray Jul. 3 at 9:55 PM
$CAPR If I read the latest filing shared by Dash_Man correctly, on pg 6 of the defendants’ brief in support of motion to compel arbitration, it says both parties have appointed arbitrators. So if I am correct, the arbitration ball is rolling, although the case for a preliminary injunction is also proceeding. NS’s argument appears to be that art. 18.3.3 of the contract (the part authorizing injunctive relief) is there only to “aid” arbitration, and every dispute is required by the contract to go to arbitration. The document also asserts that the arbitrators are the only ones who can decide if the injunction request should be heard by a judge.
2 · Reply
Latest News on CAPR
Caprock Announces Closing of Private Placement

Jun 19, 2026, 5:47 PM EDT - 14 days ago

Caprock Announces Closing of Private Placement


Capricor Therapeutics management to meet with Oppenheimer

2026-06-16T18:45:26.000Z - 18 days ago

Capricor Therapeutics management to meet with Oppenheimer


Caprock Announces Proposed Private Placement

Jun 12, 2026, 6:02 PM EDT - 21 days ago

Caprock Announces Proposed Private Placement


Capricor Therapeutics Slides: Corporate presentation

May 29, 2026, 7:00 AM EDT - 5 weeks ago

Capricor Therapeutics Slides: Corporate presentation


Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026


Capricor Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Capricor Therapeutics Earnings release: Q1 2026


Capricor Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Capricor Therapeutics Quarterly report: Q1 2026


Capricor Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Capricor Therapeutics Proxy statement: Proxy filing


Capricor Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Capricor Therapeutics Proxy statement: Proxy filing


Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T18:35:53.000Z - 4 months ago

Capricor selloff today a buying opportunity, says Roth Capital


Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025


Capricor Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Annual report: Q4 2025


Capricor Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Earnings release: Q4 2025


Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

2026-03-12T20:16:10.000Z - 4 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)


Capricor Therapeutics Transcript: Study Result

Dec 17, 2025, 1:00 PM EST - 7 months ago

Capricor Therapeutics Transcript: Study Result


Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Transcript: Status Update


Capricor Therapeutics Press release: Status Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Press release: Status Update


Capricor Therapeutics Slides: Status Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Slides: Status Update


Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025


Capricor Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Quarterly report: Q3 2025


Capricor Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings release: Q3 2025


Capricor Therapeutics Slides: Corporate Presentation

Oct 13, 2025, 7:00 AM EDT - 9 months ago

Capricor Therapeutics Slides: Corporate Presentation


Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Transcript: Study Update


Capricor Therapeutics Press release: Study Update

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Press release: Study Update


Capricor Therapeutics Registration statement: Registration Filing

Sep 10, 2025, 8:00 AM EDT - 10 months ago

Capricor Therapeutics Registration statement: Registration Filing


Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025


Capricor Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Quarterly report: Q2 2025


Capricor Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Earnings release: Q2 2025


OliverDog
OliverDog Jul. 4 at 5:03 PM
$CAPR employee incentive stock options As is very common with employee incentive option plans, Capricor's plan requires that employees holding options at the time they leave the company have to exercise any of those options within a month or so of leaving. After that window, the Company cancels the options. That is, they can hold shares bought with the options but not the options themselves. Now, the CFO and chief legal officer have recently sold a large number of shares each, shares they received after exercising options. Why? I don't think it is lack of confidence in the future of the Company. I think it is more likely it is preparation for the day their remaining vested options will be exercised, namely once the Board draws conclusions about who is most responsible for the "mistake" (#$%) in the Company's distribution agreement with NS. My speculation. It is what I would do in their position.
3 · Reply
satrasal
satrasal Jul. 4 at 3:30 PM
$CAPR I haven't read the NS brief. I'm sure it is immaterial. The arbitration carve-out in the Capricor-NS Pharma agreement does not say "except for preliminary injunctions." It exempts claims for "temporary, preliminary, or permanent injunctive relief or any other form of equitable relief." And rescission is an equitable remedy. Since equitable relief is exempt from arbitration, and since Chancery now properly takes the case to evaluate injunction, it retains jurisdiction to handle the entire case, given Judge Neal remanded the entire case and denied NS Pharma’s motion to compel arbitration. Frustration of purpose is central, and NS has plainly admitted contract unworkability. So I think we get both an injunction and rescission from Chancery. Capr moved back up the 30ish before the adcom drop to support at 22ish. The market agrees - since sept expiry premium is .5 to 1 more than Aug aug 21 expiry, despite including the pdufa; any movement is retail gaming, not instit repositioning.
1 · Reply
Dash_Man
Dash_Man Jul. 4 at 2:17 PM
$CAPR Happy 4th everyone. I am hoping Skadden highlight this logical inconsistency in their reply.
1 · Reply
Sherwoodtf
Sherwoodtf Jul. 4 at 10:30 AM
$CAPR https://www.parentprojectmd.org/events/webinar-your-voice-matters-preparing-for-the-fda-advisory-committee-meeting-on-deramiocel/?fbclid=IwZnRzaAS1v95leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeh6_D17nv_78-ec8Os9scEqBYX5lYkJnpfUdXxvdxb_nEZV-F2g5wHk_bLbc_aem_jBlIcg8d2aacU4DUAaMx7A
2 · Reply
Svenson1984
Svenson1984 Jul. 4 at 10:04 AM
$CAPR I love Capr but I am also not married to the stock. Sold shares some when Abvx dipped to the 80s as I know this was an easy short term gain. Made all the losses back from the $35 fade. Might trim my Abvx position next to by more here or SLS
0 · Reply
HamBoneXoXo
HamBoneXoXo Jul. 4 at 1:53 AM
$CAPR I would not be holding long shares in advance of adcom briefing papers because in this case, the briefing won’t be positive considering that this adcom actually coming post crl where fda rejected the drug. The briefing will be mixed to negative suggesting fda remains open to discussion but questions the validity of the efficacy analysis.
3 · Reply
nickiead
nickiead Jul. 3 at 11:51 PM
$CAPR If the court grants Capricor a preliminary injunction then it stops NS Nippon from distributing drug. The court case would continue and Capricor would distribute Deramiocel and establish a distribution network. A case like this could last for many months and possibly over a year. And although arbitration would ultimately be part of final resolution it would come at end of case not during. Capricor would then just be arbitrating a cash settlement. Bottomline if Capricor gets a temporary injunction it will basically end NS Pharma as a distributor now and in future. Nippon is desperately fighting the "irreparable harm" claim which is their only hope to stop injunction. Skadden has outlined such a strong case of proving "irreparable harm" that odds are very likely we see an expedited hearing with oral arguments in a few weeks and a preliminary injunction soon after.
1 · Reply
Jusbabysteppin
Jusbabysteppin Jul. 3 at 10:52 PM
$CAPR My bottom line is this, NS is coming after us because they want what we have. Tough shit for them , I think it’s a great sign of progress. They are first to come after capr, but more will come . After all, it’s like Willy Wonkas golden ticket! Everyone wants it!
2 · Reply
ReggieTrades
ReggieTrades Jul. 3 at 10:46 PM
1 · Reply
sueandray
sueandray Jul. 3 at 9:55 PM
$CAPR If I read the latest filing shared by Dash_Man correctly, on pg 6 of the defendants’ brief in support of motion to compel arbitration, it says both parties have appointed arbitrators. So if I am correct, the arbitration ball is rolling, although the case for a preliminary injunction is also proceeding. NS’s argument appears to be that art. 18.3.3 of the contract (the part authorizing injunctive relief) is there only to “aid” arbitration, and every dispute is required by the contract to go to arbitration. The document also asserts that the arbitrators are the only ones who can decide if the injunction request should be heard by a judge.
2 · Reply
dnfrs
dnfrs Jul. 3 at 8:31 PM
$CAPR The greatest speech in American history ends... " But, in a larger sense, we can not dedicate -- we can not consecrate -- we can not hallow -- this ground. The brave men, living and dead, who struggled here, have consecrated it, far above our poor power to add or detract. The world will little note, nor long remember what we say here, but it can never forget what they did here. It is for us the living, rather, to be dedicated here to the unfinished work which they who fought here have thus far so nobly advanced. It is rather for us to be here dedicated to the great task remaining before us -- that from these honored dead we take increased devotion to that cause for which they gave the last full measure of devotion -- that we here highly resolve that these dead shall not have died in vain -- that this nation, under God, shall have a new birth of freedom -- and that government of the people, by the people, for the people, shall not perish from the earth." Abe Lincoln November 19, 1863
0 · Reply
Dash_Man
Dash_Man Jul. 3 at 6:57 PM
$CAPR Sorry, the link to the NS filing wouldn't open for some people. Hopefully this will. https://drive.google.com/file/d/1jubZKjebFElerHkcnfrjK9zsHH6b4EJQ/view
5 · Reply
CAPPdaddy
CAPPdaddy Jul. 3 at 5:21 PM
$CAPR I saw someone post that hearing will be on July 31st. Is that legit? Where is that information pulled from? Can’t imagine they would have adcom 29th and hearing after or even within same week?
5 · Reply
Semafore
Semafore Jul. 3 at 5:05 PM
0 · Reply
Semafore
Semafore Jul. 3 at 5:05 PM
0 · Reply
Semafore
Semafore Jul. 3 at 5:05 PM
0 · Reply
Semafore
Semafore Jul. 3 at 5:04 PM
0 · Reply
haha1978
haha1978 Jul. 3 at 4:11 PM
$CAPR happy 4th of july.
0 · Reply
haha1978
haha1978 Jul. 3 at 4:10 PM
$CAPR figured out how to pay 0% on short term gains with 1 stock. Its called a Section 721 exchange. https://usecache.com/companion/what-is-an-exchange-fund
1 · Reply
ripztrip
ripztrip Jul. 3 at 3:57 PM
1 · Reply
StillFishing
StillFishing Jul. 3 at 3:44 PM
$CAPR It’s obvious NS knows they screwed up and they’ll face the music…. Just my cheap summary for ya…. It’s free too, no subscription required 😀 Happy 4th!!!
2 · Reply
Pastime
Pastime Jul. 3 at 3:33 PM
$CAPR always
0 · Reply